ACP-196 Is a Second Generation Inhibitor of Bruton Tyrosine Kinase (BTK) with Enhanced Target Specificity

被引：0
|
作者：
Harrington, Bonnie K. [1 ]
Gulrajani, Michael [2 ]
Covey, Todd [2 ]
Kaptein, Allard [3 ]
Van Lith, Bart [3 ]
Izumi, Raquel [2 ]
Hamdy, Ahmed [2 ]
Ulrich, Roger Glenn [2 ]
Byrd, John C. [4 ]
Lannutti, Brian J. [2 ]
Johnson, Amy J. [4 ]
机构：
[1] Ohio State Univ, Coll Vet Med, Columbus, OH 43210 USA
[2] Acerta Pharma, Redwood City, CA USA
[3] Acerta Pharma, Oss, Netherlands
[4] Ohio State Univ, Dept Med, Div Hematol, Columbus, OH 43210 USA
来源：
BLOOD | 2015年 / 126卷 / 23期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [31] Bruton tyrosine kinase (BTK) may be a potential therapeutic target for interstitial cystitis/bladder pain syndrome
    Wang, Guang
    Yang, Tong-Xin
    Li, Jiong-Ming
    Huang, Zi-Ye
    Yang, Wen-Bo
    Li, Pei
    He, Da-Lin
    AGING-US, 2022, 14 (17): : 7052 - 7064
  • [32] Clinical pharmacology and PK/PD translation of the second-generation Bruton's tyrosine kinase inhibitor, zanubrutinib
    Tam, Constantine S.
    Ou, Ying C.
    Trotman, Judith
    Opat, Stephen
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2021, 14 (11) : 1329 - 1344
  • [33] Ibrutinib (PCI-32765), the First BTK (Bruton's Tyrosine Kinase) Inhibitor in Clinical Trials
    Brown, Jennifer R.
    CURRENT HEMATOLOGIC MALIGNANCY REPORTS, 2013, 8 (01) : 1 - 6
  • [34] Effect and Mechanism of the Bruton Tyrosine Kinase (Btk) Inhibitor Ibrutinib on Rat Model of Diabetic Foot Ulcers
    Yang, Xuedong
    Cao, Zhenhao
    Wu, Peigang
    Li, Zhong
    MEDICAL SCIENCE MONITOR, 2019, 25 : 7951 - 7957
  • [35] The Btk tyrosine kinase is a major target of the Bcr-Abi inhibitor dasatinib
    Hantschel, Oliver
    Rix, Uwe
    Schmidt, Uwe
    Buerckstuemmer, Tilmann
    Kneidinger, Michael
    Schuetze, Gregor
    Colinge, Jacques
    Bennett, Keiryn L.
    Ellmeier, Wilf Ried
    Valent, Peter
    Superti-Furga, Giulio
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2007, 104 (33) : 13283 - 13288
  • [36] The Bruton Tyrosine Kinase (BTK) Inhibitor Acalabrutinib Demonstrates Potent On-Target Effects and Efficacy in Two Mouse Models of Chronic Lymphocytic Leukemia
    Herman, Sarah E. M.
    Montraveta, Arnau
    Niemann, Carsten U.
    Mora-Jensen, Helena
    Gulrajani, Michael
    Krantz, Fanny
    Mantel, Rose
    Smith, Lisa L.
    McClanahan, Fabienne
    Harrington, Bonnie K.
    Colomer, Dolors
    Covey, Todd
    Byrd, John C.
    Izumi, Raquel
    Kaptein, Allard
    Ulrich, Roger
    Johnson, Amy J.
    Lannutti, Brian J.
    Wiestner, Adrian
    Woyach, Jennifer A.
    CLINICAL CANCER RESEARCH, 2017, 23 (11) : 2831 - 2841
  • [37] Bruton's tyrosine kinase (Btk) inhibitor ibrutinib suppresses stem- like traits in ovarian cancer
    Zucha, Muhammad Ary
    Wu, Alexander T. H.
    Lee, Wei-Hwa
    Wang, Liang-Shun
    Lin, Wan-Wan
    Yuan, Chiou-Chung
    Yeh, Chi-Tai
    ONCOTARGET, 2015, 6 (15) : 13255 - 13268
  • [38] First-Generation and Second-Generation Bruton Tyrosine Kinase Inhibitors in Waldenstrom Macroglobulinemia
    Argyropoulos, Kimon V.
    Lia, M.
    HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2018, 32 (05) : 853 - +
  • [39] Proarrhythmic Effects of Ibrutinib, a Clinically Approved Inhibitor of Bruton'S Tyrosine Kinase (BTK) Used in Cancer Therapy
    Yang, Tao
    Moslehi, Javid J.
    Roden, Dan M.
    CIRCULATION, 2015, 132
  • [40] Analysis of the Effects of the Bruton's tyrosine kinase (Btk) Inhibitor Ibrutinib on Monocyte Fcγ Receptor (FcγR) Function
    Ren, Li
    Campbell, Amanda
    Fang, Huiqing
    Gautam, Shalini
    Elavazhagan, Saranya
    Fatehchand, Kavin
    Mehta, Payal
    Stiff, Andrew
    Reader, Brenda F.
    Mo, Xiaokui
    Byrd, John C.
    Carson, William E., III
    Butchar, Jonathan P.
    Tridandapani, Susheela
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2016, 291 (06) : 3043 - 3052
12345